Recent TEVA News
- Teva to Present at the Jefferies London Healthcare Conference • GlobeNewswire Inc. • 11/08/2024 09:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2024 09:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2024 12:00:13 PM
- Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS • GlobeNewswire Inc. • 11/06/2024 12:00:00 PM
- U.S. Index Futures Surge on Trump Victory Prospects; Commodities Slide Amid Dollar Strength • IH Market News • 11/06/2024 11:12:52 AM
- Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition • GlobeNewswire Inc. • 11/01/2024 07:05:00 PM
- Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as R • GlobeNewswire Inc. • 11/01/2024 07:00:00 PM
- Teva Statement on European Commission Decision; Company to Appeal • GlobeNewswire Inc. • 10/31/2024 11:29:54 AM
- Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab) • GlobeNewswire Inc. • 10/22/2024 11:00:00 AM
- BP Signals Rising Net Debt; Tesla Slumps; Stellantis CEO Announces Retirement; Berkshire Trims BofA Stake, and More • IH Market News • 10/11/2024 10:31:49 AM
- Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA • GlobeNewswire Inc. • 10/08/2024 11:00:00 AM
- Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate • GlobeNewswire Inc. • 10/03/2024 12:30:00 PM
- Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S. • GlobeNewswire Inc. • 10/01/2024 12:29:04 PM
- Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024 • GlobeNewswire Inc. • 09/30/2024 08:30:00 PM
- Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia • GlobeNewswire Inc. • 09/23/2024 05:00:00 AM
- Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia • GlobeNewswire Inc. • 09/21/2024 08:15:00 AM
- New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000) • GlobeNewswire Inc. • 09/21/2024 08:10:00 AM
- Teva to Present at the Bank of America 2024 Global Healthcare Conference • GlobeNewswire Inc. • 09/11/2024 08:30:00 PM
- GameStop plunges 11% on stock offering, DJT drops post-debate, GSK fails shingles vaccine trial • IH Market News • 09/11/2024 10:25:41 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 11:40:42 AM
- Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference • GlobeNewswire Inc. • 08/26/2024 09:00:00 PM
- Form 144/A - Report of proposed sale of securities: [Amend] • Edgar (US Regulatory) • 08/14/2024 11:06:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:09:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:06:50 PM
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM